In One Day, Change At Biotechs: Leiden To Replace Emmens At Vertex And At Amgen, Bradway Will Become CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Board member Jeffrey Leiden, who oversaw the commercialization of Humira at Abbott, will succeed Matthew Emmens as Vertex CEO next February.
You may also be interested in...
Amgen “Doubling Down” On Innovation As It Sets A Course For The Future
Amgen is planning to launch four new drugs in 2015 while cutting costs by $1.5 billion by 2018, all part of a big push outlined by CEO Robert Bradway Oct. 28 to drive long-term growth as Amgen’s legacy brands come under pressure.
Amgen Commits To PCSK9 Phase III, Tightening First-To-Market Race
The biotech will begin Phase III studies testing the cholesterol treatment in early 2013, about six months after Sanofi/Regeneron initiated Phase III studies of a rival drug.
Amgen Commits To PCSK9 Phase III, Tightening First-To-Market Race
The biotech will begin Phase III studies testing the cholesterol treatment in early 2013, about six months after Sanofi/Regeneron initiated Phase III studies of a rival drug.